ACRS earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -10.04. Updated 2026-07-23.
Aclaris Therapeutics (ACRS) Research Hub
Aclaris Therapeutics (ACRS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.32 USD (-4.32%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.04, market cap 0.67B. This hub links to the full technical, earnings and options research available for ACRS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.32 USD (-4.32%) |
| 52-week range | 4.26 USD – 6.6 USD |
| Trend regime | Range |
| 14-day RSI | 38.2 (Bearish) |
| Trailing P/E | -10.04 |
| Market cap | 0.67B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ACRS
Covered Call on ACRS: how it works, illustrative setup around the real 5.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACRS: how it works, illustrative setup around the real 5.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACRS: how it works, illustrative setup around the real 5.32 USD price, max profit/loss, breakeven and when to use it. Educational.
ACRS technical analysis: range, last 5.32 USD, RSI 38.2, 52w range 4.26 USD–6.6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ACRS in?
Aclaris Therapeutics (ACRS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACRS in an uptrend or downtrend?
As of 2026-09-11, ACRS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACRS's trailing P/E ratio?
ACRS's trailing P/E is -10.04, with a market cap of 0.67B. See the earnings research page for full valuation detail.
When does ACRS next report earnings?
ACRS is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.16 USD.